

IMAGION BIOSYSTEMS LIMITED

ASX: IBX

13 May 2024

Change of Company Secretary

MELBOURNE – Imagion Biosystems (ASX:IBX), a company dedicated to improving healthcare through the early detection of cancer, is pleased to announce the appointment of Ms Melanie Leydin as Company Secretary, effective today.

Ms Leydin has over 25 years' experience in the accounting profession and over 15 years as a company secretary with extensive experience in relation to public company responsibilities, including ASX and ASIC compliance, control and implementation of corporate governance, statutory financial reporting, re-organisation of Companies and shareholder relations.

Mr Geoff Hollis has resigned as Company Secretary, effective from today. The Board sincerely thank Mr Hollis for his dedication and service and wish him well for the future.

For the purposes of Listing Rule 12.6, Ms Leydin is appointed the person responsible for communications with ASX in relation to Listing Rule matters.

— ENDS —

About Imagion Biosystems

Established in 2017 and headquartered in the San Diego, California, US, Imagion Biosystems is an ASX-listed company dedicated to developing innovative medical imaging technologies for various cancer types. Imagion Biosystems is advancing clinical development of its MagSense® platform technology to revolutionize cancer diagnosis, introducing molecular imaging to MRI. The Company's lead program has demonstrated its innovative technology embodied in MagSense® HER2 Imaging Agent (MSH2IA) is safe and well-tolerated in patients diagnosed with HER2+ breast cancer. Imagion Biosystems' MagSense® pipeline includes prostate cancer, ovarian cancer, pancreatic cancer, and brain cancer programs.

For more information, visit <https://imaginationbiosystems.com/investor-hub/>

Authorisation & Additional information

This announcement was authorised by the Board of Imagion Biosystems Limited.

